Epigallocatechin-3-gallate Regulates NADPH Oxidase Expression in Human Umbilical Vein Endothelial Cells.
10.4196/kjpp.2010.14.5.325
- Author:
Hee Yul AHN
1
;
Chan Hyung KIM
;
Tae Sun HA
Author Information
1. Department of Pharmacology, College of Medicine, Chungbuk University, Cheongju 361-763, Korea. hyahn@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
EGCG;
NADPH oxidase;
Angiotensin II;
ROS;
HUVEC
- MeSH:
Angiotensin II;
Atherosclerosis;
Cardiovascular Diseases;
Catechin;
Endothelial Cells;
Human Umbilical Vein Endothelial Cells;
Humans;
NADP;
NADPH Oxidase;
Reactive Oxygen Species;
Superoxides;
Tea
- From:The Korean Journal of Physiology and Pharmacology
2010;14(5):325-329
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vascular NADPH oxidase plays a pivotal role in producing superoxide in endothelial cells and thus acts in the initiation and development of inflammatory cardiovascular diseases such as atherosclerosis. Epigallocatechin-3-gallate (EGCG), the major catechin derived from green tea, has multiple beneficial effects for treating cardiovascular disease but the effect of EGCG on the expression of vascular NADPH oxidase remains unknown. In this study, we investigated the mechanism(s) by which EGCG might inhibit the expression of subunits of NADPH oxidase, namely p47(phox), p67(phox) and p22(phox), induced by angiotensin II (Ang II) in human umbilical vein endothelial cells. Ang II increased the expression levels of p47(phox), p67(phox), and p22(phox), but EGCG counteracted this effect on p47(phox). Moreover, EGCG did not affect the production of reactive oxygen species induced by Ang II. These data suggest a novel mechanism whereby EGCG might provide direct vascular benefits for treating inflammatory cardiovascular diseases.
